- Home
- CYAB vs KPRX Comparison
CYAB vs KPRX Comparison
Compare CYAB & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CYAB | KPRX |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 10.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CYAB | KPRX |
|---|---|---|
| Price | $0.68 | $2.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 459.2K | 63.4K |
| Earning Date | 04-09-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $1.76 |
| 52 Week High | $2.99 | $4.18 |
Technical Indicators
Market Signals| Indicator | CYAB | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 33.12 | 67.01 |
| Support Level | $0.54 | $2.57 |
| Resistance Level | $1.65 | $2.94 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 67.93 | 89.71 |
Price Performance
Historical ComparisonAbout CYAB Cyabra Inc. Common Stock
Cyabra Inc is an AI-powered SaaS company that detects and analyzes online disinformation. Its platform uses machine learning to monitor social media and news data in real time, identify fake accounts and harmful narratives, and assess content authenticity and sentiment.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.